M Dror Michaelson

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Venues

Nature medicine

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JCO precision oncology

JCO oncology practice

Yeshiva University Albert Einstein College of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Yeshiva University Albert Einstein College of Medicine

United States

PHD

Publications

Douglas M Dahl, Joseph P Rodgers, William U Shipley, M Dror Michaelson, Chin-Lee Wu, William Parker, Ashesh B Jani, Fabio L Cury, Richard S Hudes, Jeff M Michalski, Alan C Hartford, Daniel Song, Deborah E Citrin, Theodore G Karrison, Howard M Sandler, Felix Y Feng, Jason Alexander Efstathiou
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Douglas M Dahl, Joseph P Rodgers, William U Shipley, M Dror Michaelson, Chin-Lee Wu, William Parker, Ashesh B Jani, Fabio L Cury, Richard S Hudes, Jeff M Michalski, Alan C Hartford, Daniel Song, Deborah E Citrin, Theodore G Karrison, Howard M Sandler, Felix Y Feng, Jason Alexander Efstathiou
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Bradley Alexander McGregor, Wanling Xie, Elio Adib, Walter M Stadler, Yousef Zakharia, Aijai Alva, M Dror Michaelson, Shilpa Gupta, Elaine T Lam, Subrina Farah, Amin H Nassar, Xiao X Wei, Kerry L Kilbridge, Lauren C Harshman, Sabina Signoretti, Lynette M Sholl, David J Kwiatkowski, Rana R McKay, Toni K Choueiri
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO precision oncology 6 (2022)
Edwin Choy, Gregory M Cote, M Dror Michaelson, Lori J Wirth, Justin F Gainor, Alona Muzikansky, Lecia V Sequist, Ryan J Sullivan, Panagiotis M Fidias, Alice Shaw, Rebecca S Heist
Phase II Study of Cabozantinib in Patients With Bone Metastasis. The oncologist 27 (7) (2022)
Daniel E Lage, M Dror Michaelson, Richard J Lee, Joseph A Greer, Jennifer S Temel, Christopher J Sweeney
Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer. Prostate cancer and prostatic diseases 24 (4) (2021)
Robert M Stern, M Dror Michaelson, Erica L Mayer, Aric D Parnes, Annemarie E Fogerty, Ann Steward LaCasce, Ryan David Nipp
Dana-Farber Cancer Institute/Mass General Brigham Fellowship Response to the COVID-19 Pandemic. JCO oncology practice 17 (9) (2021)
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, Elizabeth R Plimack, Jaime R Merchan, David F McDermott, M Dror Michaelson, Leonard J Appleman, Sanjay Thamake, Rodolfo F Perini, Naseem J Zojwalla, Eric Jonasch
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nature medicine 27 (5) (2021)
Pier Vitale Nuzzo, Jacob E Berchuck, Keegan Korthauer, Sandor Spisak, Amin H Nassar, Sarah Abou Alaiwi, Ankur Chakravarthy, Shu Yi Shen, Ziad Bakouny, Francesco Boccardo, John Steinharter, Gabrielle Bouchard, Catherine R Curran, Wenting Pan, Sylvan C Baca, Ji-Heui Seo, Gwo-Shu Mary Lee, M Dror Michaelson, Steven L Chang, Sushrut S Waikar, Guru Sonpavde, Rafael A Irizarry, Mark Pomerantz, Daniel D De Carvalho, Toni K Choueiri, Matthew L Freedman
Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nature medicine 26 (7) (2020)

M Dror Michaelson.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

M Dror Michaelson